https://qilindo.com/wp-content/uploads/2021/08/Approved-Pulsewave-explainer-video-1.mp4

Pulsewave AG

Health Monitoring

Play Video
Play Video

Video

Presentation

One Pager

Favorites

Raising

$1,500,000

in exchange for

15%

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Industry

Medical

Company Size

2-5

Patent

Pending

Location

Israel

Languages

English, Hebrew

Website URL​

A discreet monitoring device fixed on any eyeglasses frame that collects vital information, processes it via deep learning algorithms, and makes it available for doctors before CVD events can occur.

  • All day
  • Real-time
  • Long term
  • AI supported
  • Pre/Post event

Either slide & clip on, or have an Optician replace the temple ends with TempleGuard.

The Vision

Make vital information available to doctors before CVD events occur.

The Product

“TempleGuard” is a wearable device that attaches to eyeglasses and measures vital signs from behind the ear. The device combines real-time patient monitoring with AI algorithms in order to predict the development of CVD (Cardio-Vascular Disease).

Two extensive rounds of IP research with the Swiss Federal Institute of Intellectual Property showed no existing relative patents.

 

We filed a full US Patent Application (No. 17/109,934) on Dec. 2nd, 2020.

Overview

A discreet monitoring device fixed on any eyeglasses frame that collects vital information, processes it via deep learning algorithms, and makes it available for doctors before CVD events can occur.

  • All day
  • Real-time
  • Long term
  • AI supported
  • Pre/Post event

Either slide & clip on, or have an Optician replace the temple ends with TempleGuard.

The Vision

Make vital information available to doctors before CVD events occur.

The Product

“TempleGuard” is a wearable device that attaches to eyeglasses and measures vital signs from behind the ear. The device combines real-time patient monitoring with AI algorithms in order to predict the development of CVD (Cardio-Vascular Disease).

Two extensive rounds of IP research with the Swiss Federal Institute of Intellectual Property showed no existing relative patents.

 

We filed a full US Patent Application (No. 17/109,934) on Dec. 2nd, 2020.

The Team

Please Sign In or Register to view this content.

The Market

Please Sign In or Register to view this content.

Problem & Solution

17.9 million people died from CVD in 2018, representing 31% of all global deaths. 

30% of CVD monitoring devices are abandoned within 6–12 months, mainly due to inconvenience.

Our product ‘TempleGuard’ will solve the problem of a convenient & discreet vital sign monitor, which is small and capable enough to collect cardiac indicators that are associated with blood pressure and arterial stiffness in real-time, throughout the day and over the course of years.

Please Sign In or Register to view this content.

A D D M Y S T A R T U P

Get Full Access

Want to See More?

Sign up as an investor or add your startup to gain full access.
It’s absolutely free!

Don't Miss An Opportunity

Sign up as a investor and gain full access. It’s absolutely free!

New Report

Close